ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1173

Prevalence of Coronary Artery Involvement in IgG4-Related Disease Detected by Non-Gated Cross-Sectional Imaging

Matthew Charles Baker1, Lauren Taylor2, Haziq Siddiqi2, Jison Hong2 and Brian Pogatchnik2, 1Stanford University, Menlo Park, CA, 2Stanford University, Stanford, CA

Meeting: ACR Convergence 2025

Keywords: Cohort Study, Heart disease, IgG4 Related Disease, Imaging, Subclinical Cardiovascular Disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1147–1190) Miscellaneous Rheumatic & Inflammatory Diseases Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: IgG4-related disease (IgG4-RD) classically presents with a mass or diffusely enlarged organ, but it also affects blood vessels of all sizes. Coronary artery involvement (CAI) is well described but understudied. Prior work demonstrated CAI in 13 out of 361 (4%) IgG4-RD patients, however it was limited by lack of standardized screening for the evaluation of CAI1. The goal of our study was to establish a conservative estimate of the true prevalence of CAI by screening IgG4-RD patients that had prior cross-sectional imaging of the chest, regardless of whether CAI was clinically suspected.

Methods: IgG4-RD patients were identified using the STAnford medicine Research data Repository by searching all adult patients seen at Stanford University between 2/28/09 and 3/1/2023 with any clinical document containing “IgG4-related disease,” “IgG4-RD,” or “IgG4 disease.” Each chart was manually reviewed to verify the diagnosis. Cases were categorized as definite, probable, or possible IgG4-RD2. We included all patients with prior non-gated CT chest imaging. A radiologist with expertise in IgG4-RD and vasculitis reviewed the scans, and patients who had features concerning for possible CAI were recommended to obtain a gated CT of the heart or chest. After reviewing the confirmatory imaging, we calculated the prevalence of CAI, as well as the positive predictive value (PPV) for detecting CAI.

Results: Of the 250 IgG4-RD patients in the full cohort, 130 patients (52.0%) had prior non-gated chest imaging (Figure 1). Twenty patients (15.4%) had findings concerning for possible CAI. Four of the 20 patients could not be contacted due to departure from our healthcare system or death. Of the 16 remaining patients, 3 had a negative gated CT angiography (CTA) of the chest or heart, 4 had a positive gated CTA, and 7 had prior gated CTA studies obtained after the original non-gated CT chest, which were subsequently reviewed and were positive (representative images of CAI are shown in Figure 2). Additionally, 2 patients had such profound results on the initial non-gated CT chest they were deemed definitely positive without the need for a confirmatory gated CTA. As Table 1 demonstrates, patients with CAI were older (70 years vs 63 years), more likely to be male (77% vs 49%), more likely to be current smokers (23% vs 3%), more likely to have multiorgan disease (100% vs 58%), and had higher serum IgG4 concentrations (mean peak value 973 mg/dL vs 456 mg/dL). In total, 13 out of 16 patients who screened positive were confirmed to have CAI, resulting in a PPV of 81.3%. The prevalence of CAI in this cohort of patients was 13 out of 130 (10.0%).

Conclusion: By reviewing non-gated CT chest imaging to screen for IgG4-RD CAI, we observed a prevalence of CAI of 10% in our cohort. This is higher than what has been previously reported and likely represents a conservative estimate. Our results suggest that CAI is relatively common in IgG4-RD, and future studies are needed to determine which patients should be screened for CAI and whether the approach described herein has adequate sensitivity to be implemented as a screening test. References:Katz G, et al. Semin Arthritis Rheum. 2023;60:152184.Baker MC, et al. J Rheumatol. 2023;50(3):408-12.

Supporting image 1Figure 1. Cohort selection.

Supporting image 2Figure 2. IgG4-RD coronary artery involvement on computed tomography. Panel A demonstrates suspected right coronary artery thickening on a non-gated chest CT without IV contrast (large arrow), which is confirmed on gated CT angiography (Panel B; large arrow). Panel C demonstrates additional sites of disease, including the left main, left anterior descending, and proximal left circumflex (small arrows), which were not clearly apparent on the initial CT.

Supporting image 3Table 1. Demographics and characteristics of IgG4-RD patients.


Disclosures: M. Baker: Amgen, 2, Sanofi, 2, Zenas BioPharma, 2; L. Taylor: None; H. Siddiqi: None; J. Hong: None; B. Pogatchnik: None.

To cite this abstract in AMA style:

Baker M, Taylor L, Siddiqi H, Hong J, Pogatchnik B. Prevalence of Coronary Artery Involvement in IgG4-Related Disease Detected by Non-Gated Cross-Sectional Imaging [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/prevalence-of-coronary-artery-involvement-in-igg4-related-disease-detected-by-non-gated-cross-sectional-imaging/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-coronary-artery-involvement-in-igg4-related-disease-detected-by-non-gated-cross-sectional-imaging/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology